In this piece I explain the advancements in measuring methylation and how epigenetic complexity and variability is a rate-limiting step of the genomic revolution that everyone is so excited about.

In this piece I touch on small molecules, ASOs, and the new modality market. I scope in on the cell & gene therapy markets and talk about the potential role of AI/ML in this subsector.